FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119735338> ?p ?o ?g. }

• W2119735338 endingPage "2715" @default.
• W2119735338 startingPage "2710" @default.
• W2119735338 abstract "This was a randomized, double-blind, placebo-controlled parallel study in human immunodeficiency virus type 1 (HIV-1)-uninfected healthy subjects to investigate the pharmacokinetic interaction between indinavir (IDV) and ritonavir (RTV). Subjects were allocated to treatment groups of IDV given with RTV in the following milligram doses twice daily: 800 mg of IDV-100 mg of RTV (800-100 mg), 800-200, 800-400, and 400-400 mg, placebo of IDV with RTV doses of 100, 200, and 400 mg, and placebo of both IDV and RTV. Doses of both drugs were administered for 14 days with a low-fat meal and one dose on day 15 with a high-fat meal. Blood was obtained for drug concentration measurements on days 14 and 15. Seventy-three volunteers enrolled in the study: 29 men and 44 women. Fifty-three volunteers completed the study. When compared to standard historical data for 800 mg of IDV every 8 h (q8h), the IDV area under the concentration-time curve for 24 h (AUC(24)) of IDV-RTV regimens 400-400, 800-100, and 800-200 mg were at least 1.4, 2.3, and 3.3 times higher, respectively, regardless of meal. The concentrations at the end of the dosing interval were 10 to 25 times higher than that observed in the standard regimen of 800 mg of IDV q8h for IDV-RTV 800-100 and 800-200 mg regimens, respectively. RTV at 200 mg maximally enhanced the IDV profile. Improved tolerability was associated with IDV-RTV 800-100 mg versus IDV-RTV 800-200, 800-400, and 400-400 mg q12h. The advantages of IDV-RTV twice daily over 800 mg of IDV q8h include no food restrictions and twice-daily dosing. Also, the regimens achieve levels of IDV that may be helpful in suppressing strains of HIV-1 that have reduced susceptibility to IDV or other protease inhibitors." @default.
• W2119735338 created "2016-06-24" @default.
• W2119735338 creator A5033398725 @default.
• W2119735338 creator A5035049807 @default.
• W2119735338 creator A5038076269 @default.
• W2119735338 creator A5070756038 @default.
• W2119735338 creator A5072977286 @default.
• W2119735338 creator A5076766187 @default.
• W2119735338 date "2001-10-01" @default.
• W2119735338 modified "2023-09-27" @default.
• W2119735338 title "Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers" @default.
• W2119735338 cites W1856418608 @default.
• W2119735338 cites W1871950822 @default.
• W2119735338 cites W1970674820 @default.
• W2119735338 cites W2022869105 @default.
• W2119735338 cites W2067103053 @default.
• W2119735338 cites W2110123751 @default.
• W2119735338 cites W2113424737 @default.
• W2119735338 cites W2115211058 @default.
• W2119735338 cites W2121690400 @default.
• W2119735338 cites W2127840648 @default.
• W2119735338 cites W2149335010 @default.
• W2119735338 cites W2165589438 @default.
• W2119735338 cites W4250637862 @default.
• W2119735338 doi "https://doi.org/10.1128/aac.45.10.2710-2715.2001" @default.
• W2119735338 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/90721" @default.
• W2119735338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11557459" @default.
• W2119735338 hasPublicationYear "2001" @default.
• W2119735338 type Work @default.
• W2119735338 sameAs 2119735338 @default.
• W2119735338 citedByCount "57" @default.
• W2119735338 countsByYear W21197353382012 @default.
• W2119735338 countsByYear W21197353382013 @default.
• W2119735338 countsByYear W21197353382016 @default.
• W2119735338 countsByYear W21197353382017 @default.
• W2119735338 countsByYear W21197353382018 @default.
• W2119735338 countsByYear W21197353382019 @default.
• W2119735338 countsByYear W21197353382022 @default.
• W2119735338 crossrefType "journal-article" @default.
• W2119735338 hasAuthorship W2119735338A5033398725 @default.
• W2119735338 hasAuthorship W2119735338A5035049807 @default.
• W2119735338 hasAuthorship W2119735338A5038076269 @default.
• W2119735338 hasAuthorship W2119735338A5070756038 @default.
• W2119735338 hasAuthorship W2119735338A5072977286 @default.
• W2119735338 hasAuthorship W2119735338A5076766187 @default.
• W2119735338 hasBestOaLocation W21197353382 @default.
• W2119735338 hasConcept C112705442 @default.
• W2119735338 hasConcept C126322002 @default.
• W2119735338 hasConcept C142462285 @default.
• W2119735338 hasConcept C142724271 @default.
• W2119735338 hasConcept C197934379 @default.
• W2119735338 hasConcept C203014093 @default.
• W2119735338 hasConcept C204787440 @default.
• W2119735338 hasConcept C27081682 @default.
• W2119735338 hasConcept C2777210460 @default.
• W2119735338 hasConcept C2777288759 @default.
• W2119735338 hasConcept C2778375690 @default.
• W2119735338 hasConcept C2779298103 @default.
• W2119735338 hasConcept C2781413609 @default.
• W2119735338 hasConcept C2993143319 @default.
• W2119735338 hasConcept C3013748606 @default.
• W2119735338 hasConcept C71924100 @default.
• W2119735338 hasConcept C87813604 @default.
• W2119735338 hasConcept C98274493 @default.
• W2119735338 hasConceptScore W2119735338C112705442 @default.
• W2119735338 hasConceptScore W2119735338C126322002 @default.
• W2119735338 hasConceptScore W2119735338C142462285 @default.
• W2119735338 hasConceptScore W2119735338C142724271 @default.
• W2119735338 hasConceptScore W2119735338C197934379 @default.
• W2119735338 hasConceptScore W2119735338C203014093 @default.
• W2119735338 hasConceptScore W2119735338C204787440 @default.
• W2119735338 hasConceptScore W2119735338C27081682 @default.
• W2119735338 hasConceptScore W2119735338C2777210460 @default.
• W2119735338 hasConceptScore W2119735338C2777288759 @default.
• W2119735338 hasConceptScore W2119735338C2778375690 @default.
• W2119735338 hasConceptScore W2119735338C2779298103 @default.
• W2119735338 hasConceptScore W2119735338C2781413609 @default.
• W2119735338 hasConceptScore W2119735338C2993143319 @default.
• W2119735338 hasConceptScore W2119735338C3013748606 @default.
• W2119735338 hasConceptScore W2119735338C71924100 @default.
• W2119735338 hasConceptScore W2119735338C87813604 @default.
• W2119735338 hasConceptScore W2119735338C98274493 @default.
• W2119735338 hasIssue "10" @default.
• W2119735338 hasLocation W21197353381 @default.
• W2119735338 hasLocation W21197353382 @default.
• W2119735338 hasLocation W21197353383 @default.
• W2119735338 hasLocation W21197353384 @default.
• W2119735338 hasOpenAccess W2119735338 @default.
• W2119735338 hasPrimaryLocation W21197353381 @default.
• W2119735338 hasRelatedWork W2005029758 @default.
• W2119735338 hasRelatedWork W2030127456 @default.
• W2119735338 hasRelatedWork W2039491855 @default.
• W2119735338 hasRelatedWork W2044084007 @default.
• W2119735338 hasRelatedWork W2060644115 @default.
• W2119735338 hasRelatedWork W2101188719 @default.
• W2119735338 hasRelatedWork W2104446368 @default.
• W2119735338 hasRelatedWork W2150800811 @default.
• W2119735338 hasRelatedWork W2162249113 @default.

• next